- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05683600
Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older
September 26, 2023 updated by: Guangzhou Patronus Biotech Co., Ltd.
A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older
This is an international multicenter clinical trial, which is planned to be conducted in several research centers in China and Pakistan.
A randomized, double-blind, placebo-controlled design will be conducted to evaluate the efficacy, safety of LYB001 against COVID-19 as a booster dose in China.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
3000 subjects aged 18 years and older who have completed two or three doses of SARS-CoV-2 inactivated vaccine 6-18 months will be enrolled in China.
Participants are randomly assigned to LYB001 or placebo group at a ratio of 1:1 and receive one dose at day 0.
Study Type
Interventional
Enrollment (Actual)
3000
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 402760
- Bishan District People's Hospital,Chongqing
-
-
Shandong
-
Jinan, Shandong, China, 250014
- Shandong Provincial Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy subjects aged 18 years and older, including both males and females;
- Subjects who agree to participate in this clinical trial voluntarily and sign the informed consent form, are capable of providing valid identification, understanding and complying with the requirements of the clinical protocol.
- Subjects who have been vaccinated with two-dose or three-dose inactivated COVID-19 vaccine for 6-18 months (including boundary values).
- For female participants of childbearing potential, effective contraception measures should be used within 2 weeks prior to participation in this study and the results of pregnancy test is required to be negative. Participants should voluntarily agree to use effective contraceptive measures from the time of signing the informed consent form to the end of the study (effective contraceptive measures including oral contraceptives (excluding emergency contraceptives), injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.).
Exclusion Criteria:
- Receipt of any COVID-19 vaccines other than inactivated COVID-19 vaccine;
- Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg (for subjects with poorly controlled blood pressure);
- Axillary body temperature ≥ 37.3°C prior to enrolment;
- Known allergy, or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients;
- History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS);
- History of COVID-19, or positive results for SARS-CoV-2 nucleic acid or antigen tests at screening;
- Receipt of any live attenuated vaccine within 28 days prior to vaccination, and other vaccines such as subunit and inactivated vaccine within 14 days prior to vaccination;
- Receipt of blood or blood-related products, including immunoglobulins, monoclonal antibodies, within 3 months prior to vaccination; or any planned use during the study period.
Subjects with the following diseases:
- Any acute diseases or acute attacks of chronic diseases within 7 days prior to enrolment;
- Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
- Congenital or acquired immunodeficiency or autoimmune disease, or long-term receipt (>14 consecutive days) of glucocorticoid (reference value for dose: ≥20 mg/day prednisone or equivalent) or other immunosuppressive agents within the past 6 months, with exception of inhaled or topical steroids, or short-term use (≤14 consecutive days) of oral corticosteroids;
- Currently suffering from or diagnosed with infectious diseases, such as hepatitis B, hepatitis C, syphilis, AIDS etc.;
- History or family history of neurological disorders (convulsions, epilepsy, encephalopathy, etc.) or psychiatric disorders;
- Asplenia, or functional asplenia;
- Presence of severe, uncontrollable or hospitalized cardiovascular diseases, endocrine diseases, blood and lymphatic diseases, immune diseases, liver and kidney diseases, respiratory diseases, metabolic and skeletal diseases, or malignant tumors;
- Contraindications to IM injections and blood draws, such as coagulation disorders, thrombotic or bleeding disorders, or conditions that needs continuous anticoagulant usage.
- Drug or alcohol abuse (alcohol intake ≥ 14 units per week) which in the investigator's opinion would compromise the participant's safety or compliance with the study procedures;
- Pregnant or lactating females;
- Having participated or participating in COVID-19 related clinical trials, and those participating or planning to participate in other clinical trials during the study period;
- Presence of any underlying disease or condition which, in the opinion of the investigator, may place the subject at unacceptable risk, is unable to meet the requirements of the protocol, or interfere with the assessment of vaccine response.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LYB001 Booster Group
Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive 30μg LYB001 at day 0 as a booster vaccination.
|
Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
|
Active Comparator: Placebo Booster Group
Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive placebo at day 0 as a booster vaccination
|
Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First occurrence of confirmed symptomatic COVID-19 incidence rate per person-years of follow-up
Time Frame: From 14 days after the booster dose
|
First occurrence of confirmed symptomatic COVID-19 incidence rate from 14 days after the booster dose per person-years of follow-up;
|
From 14 days after the booster dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The occurrence of adverse events
Time Frame: The occurrence of adverse events within 30 mins,7 days and 28 days after each vaccination
|
The occurrence of adverse events within 30 mins,7 days and 28 days after each vaccination
|
The occurrence of adverse events within 30 mins,7 days and 28 days after each vaccination
|
The occurrence of serious adverse events (SAEs) and adverse events of special interest (AESIs)
Time Frame: Day 0 to 12 months after vaccination
|
The occurrence of serious adverse events (SAEs) and adverse events of special interest (AESIs) within 12 months after vaccination
|
Day 0 to 12 months after vaccination
|
First occurrence of confirmed severe, critical, and fatal COVID-19 incidence per person-years of follow-up
Time Frame: From 14 days after the booster
|
First occurrence of confirmed severe, critical, and fatal COVID-19 incidence from 14 days after the booster dose per person-years of follow-up
|
From 14 days after the booster
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Li Zhang, Shandong Provincial Center for Disease Control and Prevention
- Principal Investigator: Chengyong Tang, Chongqing Bishan District People's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 29, 2022
Primary Completion (Actual)
July 12, 2023
Study Completion (Actual)
July 12, 2023
Study Registration Dates
First Submitted
December 25, 2022
First Submitted That Met QC Criteria
January 11, 2023
First Posted (Actual)
January 13, 2023
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 26, 2023
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LYB001/CT-CHN-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
-
Guangzhou Patronus Biotech Co., Ltd.Yantai Patronus Biotech Co., Ltd.Active, not recruiting
-
National Vaccine and Serum Institute, ChinaZhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...Active, not recruiting
-
Guangzhou Patronus Biotech Co., Ltd.Yantai Patronus Biotech Co., Ltd.Active, not recruiting
-
Sanofi Pasteur, a Sanofi CompanyGlaxoSmithKlineCompletedCOVID-19Honduras, United States, Australia, France, New Zealand, Spain, United Kingdom
-
Jiangsu Province Centers for Disease Control and...CanSino Biologics Inc.Completed
-
Jiangsu Province Centers for Disease Control and...CanSino Biologics Inc.Completed
-
Sinovac Research and Development Co., Ltd.Active, not recruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingCOVID-19United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
-
PT Bio FarmaFakultas Kedokteran Universitas Indonesia; Faculty of Medicine, Diponegoro...Completed